
Sanofi
SNYNASDAQHealthcareDrug Manufacturers - General
Previous close
$45.85
+$0.70 · +1.55%
SNY company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Buy
Favorable setup — positive multi-factor alignment
Valuation
79
Undervalued
Momentum
38
Weakening
Sentiment
62
Bullish
Risk resilience
74
Moderate Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteSanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- Headquarters
- FR
- CEO
- Belén Garijo López
- Listed since
- Jul 1, 2002
- Employees
- 76,493
Market position
Day range
Current $45.85
52-week range
Current $45.85
- Open
- $45.31
- Previous close
- $45.15
- Volume
- 1.86M
- 0.58× average
- Average volume
- 3.19M
- Average daily volume
- Market cap
- 110.1B USD
- Beta
- 0.28
- Market reference 1
- 50-day average
- $43.4948
- +5.41% above average
- 200-day average
- $46.0343
- -0.40% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 113.34B EUR
- P/E (TTM)
- 24.14×
- P/B (TTM)
- 1.36×
- P/S (TTM)
- 1.94×
- EV / EBITDA
- 9.08×
- Earnings yield
- 7.76%
- Free cash flow yield
- 10.08%
- Dividend yield
- 5.22%
Profitability & efficiency
- Gross margin
- 72.77%
- Operating margin
- 20.58%
- Net margin
- 8.09%
- Return on equity
- 10.95%
- Return on assets
- 6.16%
- Return on invested capital
- 7.70%
Financial health
- Debt / equity
- 0.34×
- Current ratio
- 1.09×
- Altman Z-score
- 1.55
- Piotroski F-score
- 7 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (EUR) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 46.72B EUR | 44.29B EUR | 41.62B EUR | 40.56B EUR | 39.18B EUR |
| Cost of goods sold | 13.05B EUR | 13.21B EUR | 12.63B EUR | 11.88B EUR | 12.26B EUR |
| Gross profit | 33.67B EUR | 31.08B EUR | 28.99B EUR | 28.68B EUR | 26.92B EUR |
| Research and development | 7.84B EUR | 7.39B EUR | 6.51B EUR | 6.5B EUR | 5.69B EUR |
| Selling, general, and administrative | 10.24B EUR | 9.18B EUR | 8.93B EUR | 8.74B EUR | 9.56B EUR |
| Operating expenses | 24.07B EUR | 23.83B EUR | 22.03B EUR | 18.52B EUR | 18.79B EUR |
| Interest income | 331M EUR | 457.53M EUR | 530.5M EUR | 168.96M EUR | 3.13M EUR |
| Interest expense | 626M EUR | 622.58M EUR | 512.82M EUR | 384.8M EUR | 377.37M EUR |
| Depreciation and amortization | 5.68B EUR | 3.59B EUR | 4.43B EUR | 3.11B EUR | 3.35B EUR |
| Operating income | 9.6B EUR | 7.25B EUR | 6.96B EUR | 10.16B EUR | 8.13B EUR |
| Net income | 7.81B EUR | 5.56B EUR | 5.4B EUR | 8.37B EUR | 6.22B EUR |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 73%
- 8 beats, 3 misses, 0 met estimates
- Average EPS surprise
- +4.10%
- 11 comparable reports
- Latest EPS result
- 1.21
- Estimate 1.1 · Beat by 10.00%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$49.50
7.96% upsideRating distribution
27 ratingsRecent analyst actions
SNY news
Corporate actions
Annual dividends per share
Cash distributions grouped by calendar year; partial years are marked.
$2.1953
2025 complete year+15.2% since 2021
2026 partial: $2.419
$1.906
2,021
$2.044
2,022
$1.903
2,023
$2.0369
2,024
$2.1953
2,025
$2.419
2,026*
* Partial calendar year in the available dividend history.
Corporate action history
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | May 4, 2026 | $2.419Annual | May 4, 2026 | Jun 3, 2026 |
Dividend | May 9, 2025 | $2.1953Annual | May 9, 2025 | Jun 12, 2025 |
Dividend | May 9, 2024 | $2.0369Annual | May 10, 2024 | Jun 6, 2024 |
Dividend | May 30, 2023 | $1.903Annual | May 31, 2023 | Jun 23, 2023 |
Dividend | May 26, 2022 | $0.297Special | May 27, 2022 | Jun 27, 2022 |
Dividend | May 4, 2022 | $1.747Annual | May 5, 2022 | May 31, 2022 |
Ex-dividend May 4, 2026
$2.419
Annual
Record May 4, 2026 · Payment Jun 3, 2026
Ex-dividend May 9, 2025
$2.1953
Annual
Record May 9, 2025 · Payment Jun 12, 2025
Ex-dividend May 9, 2024
$2.0369
Annual
Record May 10, 2024 · Payment Jun 6, 2024
Ex-dividend May 30, 2023
$1.903
Annual
Record May 31, 2023 · Payment Jun 23, 2023
Ex-dividend May 26, 2022
$0.297
Special
Record May 27, 2022 · Payment Jun 27, 2022
Ex-dividend May 4, 2022
$1.747
Annual
Record May 5, 2022 · Payment May 31, 2022
SNY peers
ETFs holding SNY
Funds reporting this stock among their holdings, ordered by reported position size.
VanEck Pharmaceutical ETFPPH42.61M4.03%1.07B USD0.36%$116.63+1.35%
Fidelity Enhanced International ETFFENI35.72M0.31%10.96B USD0.28%$41.72+0.77%
First Trust Value Line Dividend Index FundFVD34.11M0.41%8.29B USD0.62%$50.70+0.06%
Invesco International Dividend Achievers ETFPID30.12M3.29%923.14M USD0.53%$23.1266+0.59%
Avantis International Equity ETFAVDE28.09M0.15%19.1B USD0.23%$94.26+0.87%
Portfolio Building Block World Pharma and Biotech Index ETFPBPH22.39M2.14%933.15M USD0.13%$29.5672+1.22%
GMO International Value ETFGMOI18.2M2.90%637M USD0.60%$41.625+1.35%
Brown Advisory Sustainable Value ETFBASV8.07M1.91%216.19M USD0.71%$31.9487+0.44%
VanEck Pharmaceutical ETFPPH- Market value
- 42.61M
- Weight
- 4.03%
- AUM
- 1.07B USD
- Expense ratio
- 0.36%
- Price / 1D
- $116.63+1.35%
Fidelity Enhanced International ETFFENI- Market value
- 35.72M
- Weight
- 0.31%
- AUM
- 10.96B USD
- Expense ratio
- 0.28%
- Price / 1D
- $41.72+0.77%
First Trust Value Line Dividend Index FundFVD- Market value
- 34.11M
- Weight
- 0.41%
- AUM
- 8.29B USD
- Expense ratio
- 0.62%
- Price / 1D
- $50.70+0.06%
Invesco International Dividend Achievers ETFPID- Market value
- 30.12M
- Weight
- 3.29%
- AUM
- 923.14M USD
- Expense ratio
- 0.53%
- Price / 1D
- $23.1266+0.59%
Avantis International Equity ETFAVDE- Market value
- 28.09M
- Weight
- 0.15%
- AUM
- 19.1B USD
- Expense ratio
- 0.23%
- Price / 1D
- $94.26+0.87%
Portfolio Building Block World Pharma and Biotech Index ETFPBPH- Market value
- 22.39M
- Weight
- 2.14%
- AUM
- 933.15M USD
- Expense ratio
- 0.13%
- Price / 1D
- $29.5672+1.22%
GMO International Value ETFGMOI- Market value
- 18.2M
- Weight
- 2.90%
- AUM
- 637M USD
- Expense ratio
- 0.60%
- Price / 1D
- $41.625+1.35%
Brown Advisory Sustainable Value ETFBASV- Market value
- 8.07M
- Weight
- 1.91%
- AUM
- 216.19M USD
- Expense ratio
- 0.71%
- Price / 1D
- $31.9487+0.44%
Continue in GoAI
Research SNYresearch.disclaimer











